+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The safety of biologic agents in early rheumatoid arthritis



The safety of biologic agents in early rheumatoid arthritis



Clinical and Experimental Rheumatology 21(5 Suppl 31): S203



Accompanying the excitement surrounding the prominent efficacy of biologic agents in rheumatoid arthritis (RA) has been concern regarding potential adverse effects. Data from clinical trials and pharmacovigilance has provided an assessment of their safety in patients with established RA. As biologic agents are utilized in patients with earlier disease, optimal determination of the risk/benefit will depend on continued careful monitoring, collection, reporting and analysis of safety information.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 050728215

Download citation: RISBibTeXText

PMID: 14969079


Related references

Safety of Biologic Agents in Elderly Patients with Rheumatoid Arthritis. Journal of Rheumatology 43(11): 1984-1988, 2016

Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology 51(Suppl. 5): V38, 2012

Safety of conventional drugs and biologic agents for Rheumatoid Arthritis. European Review for Medical and Pharmacological Sciences 7(5): 139-145, 2003

Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis. Rheumatology International 31(4): 481-484, 2011

Safety of disease-modifying antirheumatic drugs and biologic agents for rheumatoid arthritis patients in real-life conditions. Seminars in Arthritis and Rheumatism 44(5): 506-513, 2015

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis and Rheumatism 63(2): 337-345, 2011

The Challenge of Treating Early-Stage Rheumatoid Arthritis: The Contribution of Mixed Treatment Comparison to Choosing Appropriate Biologic Agents. Biodrugs 30(2): 105-115, 2016

Comparison of different biologic agents in patients with rheumatoid arthritis after failure of the first biologic therapy. Wiener Medizinische Wochenschrift 160(9-10): 225-229, 2010

Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Annals of Internal Medicine 151(9): 612-621, 2009

Efficacy of biologic agents in improving the Health Assessment Questionnaire (HAQ) score in established and early rheumatoid arthritis: a meta-analysis with indirect comparisons. Clinical and Experimental Rheumatology 32(3): 333-341, 2014

Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis. Expert Opinion on Drug Safety 2(4): 347-365, 2003

Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment. Biomed Research International 2014: 702701, 2014

Risk of postoperative complications in rheumatoid arthritis relevant to treatment with biologic agents: a report from the Committee on Arthritis of the Japanese Orthopaedic Association. Journal of Orthopaedic Science 16(6): 778-784, 2012

Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Bulletin of the Nyu Hospital for Joint Diseases 66(2): 77-85, 2008

Biologic agents in the treatment of rheumatoid arthritis. Current Pharmaceutical Biotechnology 1(3): 217-233, 2000